Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Literature
1.
Lucchesi M, Guidi M, Fonte C, Farina S, Fiorini P, Favre C, de Martino M, Sardi I (2016) Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. Cancer Chemother Pharmacol 77:857–864CrossRefPubMed
2.
Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A (1985) Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. J Clin Oncol 3:19–24PubMed
3.
Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT (2013) Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Anticancer Drugs 24:189–197CrossRefPubMed
4.
Borsi JD, Wesenberg F, Stokland T, Moe PJ (1991) How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 27:1006–1009CrossRefPubMed
Metadata
Title
Reply to Prof Ian J. Cohen
Authors
Maurizio Lucchesi
Iacopo Sardi
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3061-3

Other articles of this Issue 1/2016

Cancer Chemotherapy and Pharmacology 1/2016 Go to the issue

Review Article

Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

Original Article

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

Original Article

Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites

Original Article

Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma

Original Article

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Original Article

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits